Symposium - European Medical Journal

Continue

Symposiums

Dermatology
11 Mins
10 Feb 2021

Long-term Efficacy and Safety of Tildrakizumab: 5-year Results from the reSURFACE 1 and 2 Phase III Trials in Patients with Moderate-to-severe Plaque Psoriasis

Psoriasis, a chronic systemic inflammatory disease with skin manifestations, can be an impediment to daily life. Accordingly…
Cardiology
4 Mins
29 Jan 2021

Mavacamten Positively Impacts Underlying Hypertrophic Cardiomyopathy Mechanisms as Well as Cardiac Structure and Function: Findings from the EXPLORER-HCM Study

Obstructive hypertrophic cardiomyopathy (HCM) is a progressive myocardial disorder characterised by dynamic left ventricular outflow tract (LVOT)…
EMJ Oncology 9 [Supplement 1] 2021 feature image
Oncology
10 Mins
12 Jan 2021

Expanding Possibilities in EGFR-Mutated Advanced NSCLC: Interviews with Four Key Opinion Leaders

Worldwide, there were approximately 2.10 million patients diagnosed with, and 1.77 million deaths caused by, lung cancer in 2018. Approximately…
EMJ Cardiology 8 [Supplement 4] 2020 Feature Image
Cardiology
8 Mins
22 Dec 2020

Long-Term Benefits of a Holistic Approach on Dyslipidaemia Management

Prof Banach explained that current lipid-lowering therapy (LLT) with statins, ezetimibe, and proprotein convertase subtilisin/kexin Type 9 inhibitors…
Allergy & Immunology
11 Mins
22 Dec 2020

Human Milk Oligosaccharides: New Developments in the Management of Cow’s Milk Protein Allergy

This symposium, which was part of the industry programme at Food Allergy and Anaphylaxis Meeting and the European Consortium on Application…
EMJ Oncology 8 [Supplement 4] 2020 Feature Image
Oncology
6 Mins
16 Dec 2020

3rd Breast Cancer Virtual Masterclass Symposium: MONARCH 2, a Phase III Study of Abemaciclib or Placebo in Combination with Fulvestrant

More than 70% of patients diagnosed with metastatic breast cancer present with oestrogen-HR+ disease and are therefore candidates for endocrine…
Dermatology
8 Mins
15 Dec 2020

The Other Side of the Moon: A Clinical Dialogue on the IL-23 Pathway

Prof Reich began by highlighting how insights into the pathophysiology of psoriasis have led to the development and expansion of cytokine-targeted…
Derm 8.1 feature image
Dermatology
6 Mins
15 Dec 2020

Latest Highlights on Biologic Treatments for Psoriasis and Psoriatic Arthritis from EADV 2020

The VOYAGE 1 trial1 was a placebo- and active-controlled Phase III study to evaluate long-term efficacy and safety of the IL-23p19 inhibitor guselkumab…
We’ve noticed you’re accessing
from North/South America.